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E-mail: alessandra.recchia@unimore.itDeficiency of basement membrane heterotrimeric laminin 332
component, coded by LAMA3, LAMB3, and LAMC2 genes,
causes junctional epidermolysis bullosa (JEB), a severe skin
adhesion defect. Herein, we report the first application of
CRISPR/Cas9-mediated homology direct repair (HDR) to in
situ restore LAMB3 expression in JEB keratinocytes in vitro
and in immunodeficientmice transplantedwith genetically cor-
rected skin equivalents. We packaged an adenovector carrying
Cas9/guide RNA (gRNA) tailored to the intron 2 of LAMB3
gene and an integrationdefective lentiviral vector bearing a pro-
moterless quasi-complete LAMB3 cDNA downstream a splice
acceptor site and flanked by homology arms. Upon genuine
HDR, we exploited the in vitro adhesion advantage of laminin
332 production to positively select LAMB3-expressing kerati-
nocytes. HDR and restored laminin 332 expression were evalu-
ated at single-cell level. Notably, monoallelic-targeted integra-
tion of LAMB3 cDNA was sufficient to in vitro recapitulate
the adhesive property, the colony formation typical of normal
keratinocytes, as well as their cell growth.Grafting of genetically
corrected skin equivalents onto immunodeficient mice showed
a completely restored dermal-epidermal junction. This study
provides evidence for efficient CRISPR/Cas9-mediated in situ
restoration of LAMB3 expression, paving the way for ex vivo
clinical application of this strategy to laminin 332 deficiency.
INTRODUCTION
Junctional epidermolysis bullosa (JEB) is a recessively inherited skin
disorder characterized by fragility of the skin and mucous membranes
andby tissue separationwithin the lamina lucida of the cutaneous base-
ment membrane zone (BMZ). The majority of JEB cases are caused by
defects in laminin 332, the major adhesion ligand of basal epithelial
cells expressed in the BMZ of the skin and mucous epithelia. Laminin
332 is a multi-domain glycoprotein formed by 3 subunits, a3, b3, and
g2, coded by LAMA3, LAMB3, and LAMC2 genes, respectively.
Restored expression of laminin 332 protein in defective skin keratino-
cytes by gene addition strategies results in a complete re-establishmentMolecular Therapy Vol. 26 No 11 Novemof the adhesion property of keratinocytes in vitro1,2 and in a permanent
correction of a normal dermal-epidermal junction in vivo.3,4
The gene addition strategy based on viral (e.g., adeno-associated virus
[AAV] and lentiviral and retroviral vectors) delivery of an expression
cassette for the correct gene has been the strategy of choice to treat
severe genetic disorders, e.g., junctional3,4 and dystrophic epidermol-
ysis bullosa (DEB),5 hemophilia B,6 and X-linked severe combined
immunodeficiency (SCID-X1).7 The gene addition strategy has
shown excellent results over the years in many cell contexts and
with multiple vectors and genes. However, permanent correction of
disease-causing mutations or locus-specific insertion of a therapeutic
cDNA remains preferable to allow long-term physiological and tis-
sue-restricted expression of the introduced sequence.
In the last years, emerging genome-editing strategies, able to modify
nucleic acids within disease-affected cells and tissues, have shown
therapeutic potential for the treatment ofmonogenic, highly penetrant
diseases, such as SCID-X18 and hemophilia B.9 Among the fourmajor
classes of nucleases, meganucleases,10 zinc finger nucleases (ZFNs),11
transcription activator-like effector nucleases (TALENs),12 and
CRISPR-associated nuclease Cas9,13 CRISPR/Cas9 system from
S. pyogenes (SpCas9) clearly boosted the applications of genome edit-
ing to gene therapy. It has turned out that Cas9-mediated homologous
recombination (HR) of a donorDNA template offers a valuable option
to correct the mutated genes associated to monogenic disorders.14,15
This study aims for the first time to apply CRISPR/Cas9-triggered
HR to in situ re-establish LAMB3 expression by integrating an almost
complete LAMB3 cDNA. We employed, as therapeutic donor, a pro-
moterless LAMB3 cDNA engineered to be transcriptionally silentber 2018 ª 2018 The American Society of Gene and Cell Therapy. 1
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curs, upon HR event. This donor design overcomes most of the safety
concerns of gene therapy andholds several advantages: (1) site-specific
integration with transgene regulation and transcription controlled by
the endogenous promoter; (2) quasi-complete LAMB3 cDNA (exon
3–23), thus tackling most of the mutations mapped in JEB patients;
(3) lack of a promoter in the donor template vector, thus reducing
the probability of activating neighboring oncogenes if undesired
donor integration occurred; and (4) canonical splice acceptor site of
LAMB3 gene conferring high expression of laminin 332, which is
required to restore the in vitro adhesion property of corrected kerati-
nocytes. Restoration of laminin 332 expression in the keratinocyte cul-
ture has been demonstrated to provide a biological system to positively
select gene-corrected cells,16 avoiding cell sorting that could impair
cell viability, or antibiotic selection, not feasible inmany clinical appli-
cations. Thus, exploiting the in vitro adhesion advantage of laminin-
332-corrected keratinocytes, we propose a novel and safe gene editing
strategy to in situ restore LAMB3 expression upon canonical splicing
event in the defective gene of JEB keratinocytes.
In this study, a LAMB3 editing strategy was applied to keratinocytes
from two JEB patients: the first carrying a homozygous frameshift mu-
tation (c.1945dupG) in the exon 14 of LAMB3 gene, leading to the for-
mation of a premature stop codon within exon 15 (p.A649fsX38),17
and the second carrying a frequent (45%–63%) homozygous
c.1903C > T transition in the exon 14 of LAMB3 gene, resulting in
an Arg635-to-ter (R635X) substitution.18 To restore the expression
of wild-type LAMB3 gene, we designed two molecular tools: a guide
RNA (gRNA) for SpCas9 targeting LAMB3 intron 2 and a promoter-
less LAMB3 cDNA (exon 3–23) flanked by a splice acceptor and a
poly-adenylation (pA) sites and embedded between two homology
arms (HAs) flanking the target site. JEB keratinocytes were co-trans-
duced with an adenoviral vector carrying expression cassettes for
SpCas9 and gRNA (AdCas9gRNA) and non-integrating lentiviral vec-
tor bearing the therapeutic donor template (IDLV-L.B3). Transduced
cells were positively selected in vitro exploiting physiological adhesion
advantages of gene-corrected cells. Molecular analysis on single iso-
lated clones demonstrated an in situmonoallelic and biallelic integra-
tion of the therapeutic donor template restoring the expression of lam-
inin 332 heterotrimer. LAMB3-corrected clones showed morphology
and adhesive properties comparable to wild-type (WT) keratinocytes
and increased proliferation with respect to JEB cells. A functional
reconstruction of dermal-epidermal junction was demonstrated in
immunodeficient mice transplanted with skin equivalents from cor-
rected clones. This study represents the first proof that in situ integra-
tion of wild-type LAMB3 cDNA spanning from exon 3 to 23 is able to
correct the JEB phenotype in vitro and in a mouse model.
RESULTS
Correction of Keratinocytes from a JEB Patient by CRISPR/
Cas9-Mediated Homology Direct Repair of Promoterless
LAMB3 cDNA
JEB disease exhibits heterogeneity in the location and number of
mutations in LAMB3 gene. To tackle a wide range of JEB-causative2 Molecular Therapy Vol. 26 No 11 November 2018mutations spread all along the transcription unit of LAMB3 gene,
we employed CRISPR/SpCas9 system. We designed a gRNA tailored
to the second intron of LAMB3 gene to trigger site-specific HR of a
promoterless LAMB3 cDNA (Figure 1A). The therapeutic LAMB3
donor carried the splice acceptor site of exon 3 followed by a super
exon consisting of correct cDNA from exon 3 to 23 and a bovine
growth hormone (bGH) pA site. This promoterless therapeutic donor
cassette, flanked by HAs, was cloned in reverse orientation into an
integration defective lentiviral vector (IDLV-L.B3) in order to avoid
cryptic splicing site in 50 long terminal repeat (LTR),19 leading to
expression of truncated proteins (Figure 1A). SpCas9 and gRNA
were cloned into a first-generation adenoviral vector (AdCas9gRNA)
able to efficiently transduce human keratinocytes.20,21
The nuclease-mediated in situ integration of the therapeutic LAMB3
donor was addressed in immortalized keratinocytes derived from
a JEB patient carrying the c.1945dupG LAMB3 mutation (referred
to as JEB.A649fsX38). This homozygous mutation maps on exon 14
and results in a frameshift starting at codon 649 and leading
to the formation of a premature stop codon within exon 15
(p.A649fsX38).17 As a consequence, the mutant mRNA is degraded
by nonsense-mediated mRNA decay mechanism and, in case of
occurring protein synthesis, translated in a b3 chain truncated in
the rod domain, which is required for laminin-332 assembly. Thus,
the mutation leads to a complete loss of LAMB3 expression.
We first transduced JEB.A649fsX38 keratinocytes with increasing
doses of AdCas9gRNA vector (MOI 104, 2  104, 5  104, and 105
vector genomes [vg]/cell) to evaluate gRNA editing efficiency. Sur-
veyor assay of AdCas9gRNA-transduced cells clearly showed editing
at all tested MOIs (Figure S1). To determine indels frequency,
tracking of indels by decomposition (TIDE) analysis22 on PCR ampli-
cons derived from transduced JEB.A649fsX38 cells was performed
and showed 25%, 41%, 67%, and 76% (p < 0.05) of indels, respectively
(Figure S2). Indels types upon AdCas9gRNA delivery (MOI 2  104
vg/cell) was more accurately evaluated by bioinformatics analysis
(D.B., V. Marigo, and A.R., unpublished data) of single Sanger se-
quences (Figure S3) and resulted in 56.3% total indels, in particular
40.8% insertion, 14.1% deletion, and 1.4% mismatches. To note,
higher doses resulted in toxic effect; thus, the MOI 104 and 2  104
vg/cell were selected for LAMB3-editing experiment. We co-trans-
duced JEB.A649fsX38 keratinocytes with AdCas9gRNA (MOI 104
and 2  104 vg/cell) and IDLV-L.B3 (4.32  102 vg/cell) vectors.
Targeted integration (TI) PCR confirmed that homology direct repair
(HDR) events precisely occurred, as demonstrated by attended bands
at both 50 and 30 vector-genome junctions (Figure 1B). However,
flow cytometric analysis of laminin 332 expression in co-transduced
JEB.A649fsX38 keratinocytes showed that, as previously observed,20
the HDR frequency was barely detectable (% LAMB3+ cells =
0.48 ± 0.19; Figures 1C and S4), remarking the requirement of
positively selecting LAMB3-expressing cells.
To predict the most likely off-target sites of gRNA, we used public
webservers (http://crispr.mit.edu; https://crispr.dbcls.jp)23 to assess
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Figure 1. CRISPR/Cas9-Mediated HDR into Intron 2
of LAMB3Gene in Keratinocytes Derived from a JEB
Patient
(A) (Top) Endogenous mutated LAMB3 gene carrying
23 exons (Ex) is schematized (not in scale). The arrow
above the promoter region (P) indicates the transcription
start site; Cas9 target site and the ATG are depicted.
Sequences of the selected gRNA and PAM on intron 2
are reported. The asterisk indicates LAMB3 mutations
generating a stop codon. (Middle) Schematic represen-
tation (not in scale) of promoterless LAMB3 donor (4.5 kb
in length) cloned in opposite orientation into IDLV back-
bone, generating IDLV-L.B3 vector, is shown. (Bottom)
HDR event into the target site re-establishing the tran-
scription of corrected LAMB3 cDNA is shown. HA, ho-
mology arm (90 bp HA50 and 413 bp HA 30); pA, poly-
adenylation site (278 bp); SA, splicing acceptor; SIN-LTR,
self-inactivating long terminal repeat (LTR); WPRE, post-
transcriptional regulatory element of woodchuck hepatitis
virus. P1–4 represent primers used for targeted integra-
tion and allele discrimination PCRs. 50 (395 bp) and 30
(1,028 bp) TIs indicate the size of amplicons generated
upon genuine HDR event. (B) PCR analyses on genomic
DNA from JEB.A649fsX38 cells transduced with IDLV-
L.B3 (4.32  102 vg/cell) in absence or in presence with
AdCas9gRNA at indicated MOIs (vg/cell) or not trans-
duced. Two couple of primers specific for 50 and 30 vector
genome junctions (P1+P2 and P3+P4, respectively, as
depicted in A) amplified 395- and 1,028-bp bands
indicated by arrows, respectively, are shown. M, 1 kb
molecular weight marker. (C) Flow cytometric analysis of
laminin 332 expression in JEB.A649fsX38 cells not
transduced (NT), co-transduced with IDLV-L.B3 (4.32 
102 vg/cell) + AdCas9gRNA (MOI 104 vg/cell), and in WT
keratinocytes (Ker), after feeder exclusion (left panel). The
boxed gates represent the percentage of LAMB3-positive
keratinocytes (0.9%, 1.34%, and 82.1%).
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dicted positional bias of a given mismatch in gRNA protospacer
sequence and total number of mismatches to the intended target
site. The CRISPR design tool scored a total of 186 potential off-target
sites in the human genome (data not shown). The top 7 potential off-
target sites (Table S1) were assessed by Surveyor assay and TIDE anal-
ysis on JEB.A649fsX38 cells transduced at MOI 2 104 vg/cell. None
of the 7 predicted off-target loci showed detectable levels of off-target
gene modification by Surveyor assay (Figure S5A). TIDE analyses
scored a 0.9% frequency of indels in the OT7, although no significant
(p < 0.05) level of indels was measured for the other off targets (OTs)
(Figure S5B).MolecSelective Advantage of LAMB3-Corrected
JEB Keratinocytes In Vitro
Taking advantage of in vitro adhesion proper-
ties of LAMB3-expressing cells,1 we selected
bulk populations of LAMB3-corrected kerati-
nocytes by 2 rounds of cell detachment
from tissue culture plates using a trypsin solu-tion. The restored expression of LAMB3 gene conferred to
JEB.A649fsX38 keratinocytes an increased adhesion to a 3T3 feeder
layer seeded onto the tissue culture plate with respect to untreated
cells and to JEB.A649fsX38 treated with IDLV-L.B3 alone. Indeed,
qRT-PCR analysis before selection showed a barely detectable
increase of LAMB3 mRNA in co-transduced bulks compared to
control JEB.A649fsX38. Conversely, after two rounds of selection,
LAMB3 expression in co-transduced JEB.A649fsX38 cells was a
6- or 7-fold higher respect to untreated cells (Figure 2A). We further
evaluated the enrichment of LAMB3-corrected keratinocytes by
flow cytometry of laminin 332 expression. Up to 17% laminin-
332-positive cells were detected in co-transduced JEB.A649fsX38ular Therapy Vol. 26 No 11 November 2018 3
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Figure 2. Restored LAMB3 Expression in Gene-Corrected Keratinocytes
Selected by In Vitro Adhesion Strategy
(A) qRT-PCR analysis on LAMB3 expression in JEB.A649fsX38 keratinocytes
bulks transduced with IDLV-L.B3 (4.32  102 vg/cell) alone or in combination with
AdCas9gRNA vector at increasing MOIs (vg/cell). LAMB3 expression was
measured in JEB.A649fsX38 cells before and after 2 rounds of selections and in WT
keratinocytes, as control. Data are representative of three independent PCR am-
plifications (mean ± SEM; n = 3). (B) Representative experiment of flow cytometric
analysis of LAMB3+ cells before and after selection of JEB.A649fsX38 keratinocytes
co-transduced with IDLV-L.B3 (4.32 102 vg/cell) and AdCas9gRNA (MOI 104 and
2  104 vg/cell). The frequency (%) of LAMB3-positive cells was determined after
subtraction of background measured in not transduced cells. (C) Genomic analysis
of 50 TI in pre- and post-selected JEB.A649fsX38 keratinocytes co-transduced with
IDLV-L.B3 (4.32 102 vg/cell) and AdCas9gRNA (MOI 104 and 2 104 vg/cell). The
size of PCR bands corresponding to genuine HR (395 bp, black arrow) and
HR-independent (approximately 1,400 bp, white arrow) integration of the donor
template is indicated. The bottom gel shows PCR amplification targeting the
GAPDH (glyceraldehyde-3-phosphate dehydrogenase) gene. M, 100-bp molecular
weight marker.
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enrichment of LAMB3-corrected cells after 2 rounds of selection
(Figure 2B).4 Molecular Therapy Vol. 26 No 11 November 2018The positive selection was also confirmed at genomic level by 50 TI
PCR performed pre- and post-2 rounds of detachment (Figure 2C),
pointing out that the selective adhesion procedure enriched cells un-
dergone genuine HR event and splicing between the genomic splice
donor site in exon 2 and the splice acceptor site of exon 3 cloned up-
stream LAMB3 cDNA. As shown in Figure 2C, the adhesion strategy
negatively selected the HR-independent integration of the donor tem-
plate represented by an 1,400-bp PCR band amplified in co-trans-
duced JEB.A649fsX38 cells pre-selection. Sequencing of the PCR
band indicated the in situ integration of the 30 end of IDLV vector
(Figure S6).
The selective advantage of LAMB3-corrected cells was also demon-
strated in immortalized JEB keratinocytes carrying the R635X muta-
tion (referred to as JEB.R635X),18 which is responsible for complete
loss of laminin 332 expression. JEB.R635X keratinocytes were trans-
duced with AdCas9gRNA (MOI 2  104 vg/cell) in presence or
absence of IDLV-L.B3 (4.32 102 vg/cell). Three days post-transduc-
tion, we investigated the presence and frequency of indels in the target
site by Surveyor assay and TIDE analysis. The results reported in
Figures S7A and S7B showed a 56.7% of indels in JEB.R635X
keratinocytes transduced with AdCas9gRNA vector. Co-transduction
of JEB.R635X cells resulted in expected HDR event as demonstrated
by 50 and 30 TI PCRs (Figure S7C). After 2 rounds of selection,
we verified the enrichment of LAMB3-corrected cells by 50 TI
PCR, qRT-PCR, and flow cytometry as previously performed in
JEB.A649fsX38 keratinocytes pre- and post-selection. The results
(Figures S7D–S7F) demonstrated the positive selection of cells
undergoing genuine HR events and the restored LAMB3 expression
in co-transduced JEB.R635X keratinocytes respect to control cells.
Restored LAMB3 Expression in Selected Single-Cell Clones
To molecularly characterize the in situ integration of LAMB3 cDNA,
enriched JEB.A649fsX38 keratinocytes were cloned by limiting cell
dilution. Twenty-four out of 54 clones derived from AdCas9gRNA
(MOI 104 vg/cell) infection and 15 out of 34 clones from higher dose
(MOI 2  104 vg/cell) resulted positive in 50 and 30 TI PCR analyses
(Figures S8A and S8B), indicating that more than 2 rounds of selective
adhesion would be required to fully enrich for LAMB3-corrected
clones. Remarkably, the percentage of corrected clones was 44% from
both bulk populations, indicating that AdCas9gRNA-tested doses did
not influence the frequency of HR. Eight out of 39 clones, equally
distributed in the two bulk keratinocytes, showed a 30 TI PCR longer
than expected (Figures S9A and S9B).Deeper investigation of this aber-
rant HR event revealed an in situ integration of the 50 end of the IDLV
vector (Figures S9C and S9D). Nevertheless, these clones correctly
expressed LAMB3 mRNA (Figure S10A). For further analysis, we
expanded 28 LAMB3-corrected clones and 10 negative clones for
targeted integration PCR assay. First, we analyzed allelic distribution
of targeted clones with a PCR-based allelic discrimination strategy
employing 3 primers (P1, P2, and P4) schematized in Figure 1A.
Twenty-four and four targeted clones displayed monoallelic and bial-
lelic integration of the therapeutic donor, respectively (Figures 3A
and S10B), meaning that, in the vast majority of clones, only one allele
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Figure 3. Molecular Characterization of LAMB3-
Corrected Clones
(A) Allelic discrimination: a three-primer-based (P1, P2,
and P4; see Figure 1A) PCR approach was employed to
discriminate between parental allele (628 bp; P1+P4;
white arrow) and targeted allele (395 bp; P1+P2; black
arrow). Monoallelic clones hosting one copy of the
therapeutic donor showed both PCR bands. Biallelic
clones hosting two copies of the therapeutic donor dis-
played only 395-bp band. M, 100-bp molecular weight
marker. (B) qRT-PCR analysis on LAMB3 expression
in representative clones with respect to untreated
JEB.A649fsX38 keratinocytes and WT keratinocytes
(Ker). Data are representative of three independent PCR
amplifications (mean ± SEM; n = 3). (C) Western blot
analysis showing laminin 332 expression in lysates from
representative clones using an antibody against Kalinin
B1 (an alternative name of laminin subunit beta-3 protein).
b-actin staining served as loading control. Wild-type
keratinocytes (Ker wt) and JEB.A649fsX38 keratinocytes
(JEB) are used as positive and negative controls,
respectively. Neg. indicates a negative clone. Protein
molecular weights are indicated (kDa).
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inin 332 expression was rescued upon splicing between genomic and
donor template splice sites in all 50 and30 TI-positive clones as indicated
byqRT-PCR (Figure 3B) andwestern blot analysis (Figure 3C) reported
for representative 19 clones. Laminin 332 expression, both in terms of
RNA and protein level, was variable but always stronger than in nega-
tive clones or JEB.A649fsX38 cells, ranging from 5- to 12-fold (Fig-
ure 3B). Microscopic appearance of representative corrected and con-
trol clones seeded on a feeder layer confirmed that LAMB3-corrected
clones formed colonies comparable to normal keratinocytes (Fig-
ure 4A), as previously demonstrated.1 These clones seeded onto lethally
irradiated feeder layer were characterized by the formation of large and
round colonies surroundedby feeder cells, due to the expression of lam-
inin 332 conferring adhesion to extracellular matrix proteins produced
by feeder layer.24 In contrast, negative clones maintained the impair-
ment to generate colonies, which is typical of JEB keratinocytes. Resto-
ration of adhesive properties of LAMB3-expressing clones was also
demonstrated by longer detachment time compared to negative clones.
The detachment time for LAMB3-expressing clones was comparable
to normal keratinocytes (16 min), and negative clones as well as
JEB.A649fsX38 cells detached after 5 min of trypsin treatment (Fig-
ure 4B). LAMB3-expressing clones showed higher proliferation rate
compared to negative clones, as assessed in vitro by 3-(4,5-dimethylth-
iazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay (Figure 4C).
The kinetics of cell growth of laminin-332-expressing clones appeared
faster at all time points considered (48, 72, and 96 hr) and was more
pronounced at the latest time point.MolecLaminin 332 Restoration in a Human-Murine
Skin Graft Model
To determine whether LAMB3-corrected
JEB.A649fsX38 keratinocytes sustain laminin332 expression in vivo, skin equivalent (SE) generated from
two clones displaying monoallelic integration of the therapeutic
donor (no. 15 and no. 28), one un-corrected clone (no. 71), and
untreated JEB.A649fsX38 keratinocytes (data on untreated cells
are not shown) were grafted subcutaneously in the back of immuno-
deficient mice.
Four weeks post-transplantation, macroscopic analysis of engrafted
areas clearly showed regenerated skin in mice grafted with LAMB3-
corrected clones (no. 15 and no. 28) and heavily blistered skin in
mice grafted with un-corrected clone (no. 71; Figure 5A). Skin bi-
opsies were excised to perform histological, immunofluorescence,
and molecular analysis. H&E staining of negative clone-derived SE
showed JEB typical blistering phenotype, which was completely
reversed in corrected clones. In SE derived from clone no. 71,
epidermis (E) completely detached from dermis (D), and SEs derived
from clones no. 28 and no. 15 showed continuous dermal-epidermal
junction and visible stratification (Figure 5B). Staining using an
antibody against human laminin 332 showed strong labeling along
the basal membrane in the engrafted SEs derived from genetically
corrected clones (no. 15 and no. 28) and undetectable labeling in
the SE derived from the negative clone (no. 71; Figure 5C). Genomic
DNA from E and D derived from clone no. 71 were included in the
molecular assays run on biopsies from LAMB3-corrected SE.
Targeted integration PCR analyses confirmed the genuine HR of
the donor template into Cas9 target site only in biopsies derived
from LAMB3-corrected SE (Figure 5D). qRT-PCR analysis showedular Therapy Vol. 26 No 11 November 2018 5
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Figure 4. Phenotypic Analysis of LAMB3-Corrected
Clones
(A) Microscopic appearance of representative LAMB3-
corrected clones (no. 36 and no. 65) grown on feeder
layer. As control, negative clone (no. 71) and WT kerati-
nocytes are shown. (B) Detachment time graph indicates
the minutes (min) required to 20 LAMB3-corrected clones
and 10 negative clones to lose the adhesion properties
upon trypsin solution treatment. WT keratinocytes’
detachment time is indicated by a dashed line. (C) In vitro
proliferation of LAMB3-corrected clones (pos) versus
negative clones (neg) during time (48, 72, and 96 hr).
Results are expressed as fold change from untreated
JEB.A649fsX38 keratinocytes at 24 hr, which is set at 1.
The bars represent the mean of 3 independent experi-
ments (mean ± SEM; n = 3). p values are indicated.
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(Figure 5E) over SE from clone no. 71. These data indicate that mono-
allelic in situ integration of the therapeutic donor sustains sufficient
laminin 332 expression to restore the dermal-epidermal junction
in vivo, in a xenotransplantation model of human SEs on immunode-
ficient mice.DISCUSSION
Recently, gene editing approaches were proposed to treat severe
diseases, viral infection,25 and monogenic disorders.26–35 Any evi-
dence on nuclease-mediated gene editing approach to restore lam-
inin 332 protein, defective in JEB, has not been reported so far.
The gene addition strategy based on viral vectors carrying an
expression cassette for the correct gene has been the solely avail-
able strategy to correct genetic defects for many years. As regards
to devastating skin disorders, successful gene therapy protocols
based on autologous transplantation of skin keratinocytes trans-
duced with a g-retroviral vector expressing LAMB3 or COL7A1
cDNA were reported to treat JEB3,4 and recessive DEB,5 respec-
tively. However, gene editing approaches aimed to permanently
correct disease-causing mutations or in situ integrate therapeutic6 Molecular Therapy Vol. 26 No 11 November 2018cDNA remain an attractive and preferable
alternative over the gene addition strategy.
Correction of a single mutation or replacement
of quasi-complete gene employs the in situHDR
mechanism triggered by nuclease-mediated
double-strand breaks (DSBs). A limiting draw-
back of HDR-mediated correction in clinically
relevant cells, e.g., keratinocytes, is represented
by the low efficiency of recombination, as
reported also by other studies.20,34 However,
laminin 332 restoration in JEB keratinocytes
confers adhesion and proliferation advantages
to corrected cells,16 which could be therefore
selected without the need of antibiotic selectionor cell sorting. This observation prompted us to apply CRISPR-medi-
ated HDR to safely in situ integrate a therapeutic LAMB3 cDNA in
JEB keratinocytes.
To restore laminin 332 expression in JEB keratinocytes carrying
A649fsX38 or R635X mutation in LAMB3 gene, we employed a
first-generation adenoviral vector carrying SpCas9 coupled to a single
gRNA tailored to intron 2 of LAMB3 gene and an IDLV vector
bearing the promoterless LAMB3 cDNA (exon 3–23) flanked by
HA. This strategy was designed to potentially address a variety of mu-
tations mapped in LAMB3 gene,36,37 to maintain the transcriptional
regulatory elements of the endogenous gene, to optimize laminin
332 expression through a physiological splicing event, and to avoid
the activation of neighboring oncogenes if undesired donor integra-
tion occurred. The choice of vectors to deliver Cas9 system and the
donor template was based on our previous gene editing experience
on human keratinocytes.20,21 The top-ranked predicted off-targets
associated to the designed gRNA did not show presence of indels
by Surveyor assay, nevertheless 0.9% indel frequency was detected
for OT7 by TIDE, suggesting that genome-wide analysis of
off-targets performed by next generation sequencing (NGS)38,39
or GUIDE sequencing (GUIDE-seq)40 will be necessary before
AB
C
D E
Figure 5. In Vivo Skin Regeneration from LAMB3-Corrected Clones
(A) White light epi-illumination of grafts (cyan dotted lines) derived from 2monoallelic corrected clones (no. 15 and no. 28) and 1 negative clone (no. 71) showed regeneration
of human skin transplanted onto immunodeficient mice. (B) H&E staining of skin grafts 4 weeks after transplantation showed normal epidermal differentiation. Cyan dotted
lines border the mouse (Mo) and the engrafted human skin (Hu). The arrows indicate BMZ. (C) Immunostaining of laminin 332 confirmed the complete restoration of
epidermal-derma junction. The scale bar represents 50 mm. (D) 50 and 30 TI PCR on genomic DNA extracted from skin biopsies. The size of PCRbands is indicated. (E) LAMB3
expression in skin biopsies evaluated by qRT-PCR. D, derma; E, epidermis. Data are representative of three independent PCR amplifications (mean ± SEM; n = 3).
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Genomic analysis of bulk keratinocytes revealed predominant
genuine HDR events and rare undesired HDR-independent integra-
tion of IDLV-L.B3 donor, as previously observed using similarIDLV donors43,44 (and unpublished data). After 2 rounds of cell
detachment, we positively selected cells undergoing a predetermined
splicing event, thus expressing the laminin 332 protein that
confers adhesive and proliferative advantages. Cells carryingHDR-in-
dependent integration of IDLV-L.B3 were negatively selected as
demonstrated by genomic analysis of treated JEB bulks and expandedMolecular Therapy Vol. 26 No 11 November 2018 7
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the presence of low-frequency (<1%) HDR-independent events
in treated JEB keratinocytes, maybe undergoing aberrant splicing
affecting LAMB3 mRNA expression and thereby poor in vitro
adhesion. 50 TI PCR on single isolated clones showed that 44%
(39 out 88) of expanded clones correctly integrated the donor template
by HDR, showing monoallelic correction in the vast majority of them
(85%), independently from AdCas9gRNA doses. Based on our previ-
ous experience in wild-type keratinocytes20 and on flow cytometric
analysis reported in this study, the HDR frequency without selection
was <0.5%, thus remarking that selection of gene-corrected cells is
needed. Eight clones out of 39 hosted the 50 end of IDLV-L.B3 vector
downstream bGH pA signal, further supporting the evidence that
HDR-independent integration could be tolerated unless it does not
affect LAMB3 mRNA expression, as demonstrated by RT-PCR anal-
ysis. However, the majority of clones screened by 50 TI PCR resulted
negative for genuine HDR events, indicating that an optimization of
the adhesion-based selection protocol is required. Additional rounds
of selection, different detachment time, or lower confluency of the
transduced cultures could confer significant improvements to the
procedure. Indeed, the experiments performed on JEB.R635X
keratinocytes indicated that the adhesion selection protocol set up
for JEB.A649fsX38 cells resulted in lower enrichment of LAMB3-
expressing cells. Analysis at RNA and protein level on isolated
JEB.A649fsX38 clones scored laminin 322 expression in all corrected
clones. To note, laminin 332 expression level in monoallelic clones,
which represent the vast majority of LAMB3-corrected clones, was
sufficient to recapitulate the adhesive properties and the colony
formation typical of normal keratinocytes, as well as their cell growth.
Immunodeficient mice were transplanted with SE derived from
2 monoallelic LAMB3-corrected JEB.A649fsX38 clones, 1 un-cor-
rected clone, and untreated JEB.A649fsX38 cells. Histological and
immunofluorescence analysis showed a completely restored dermal-
epidermal junction in biopsies of SE derived from LAMB3-corrected
clones and a marked and complete detachment of human dermis to
epidermis in un-corrected clone and in untreated JEB.A649fsX38 cells.
Molecular analyses on DNA and RNA extracted from biopsies
confirmed the genuine HR event and the physiological splicing event
leading to 20-fold expression of LAMB3mRNA over un-corrected or
untreated JEB.A649fsX38 cells. Overall, these data provide evidence of
the functional correction of laminin 332 defect in vivo.
This study represents the first promising application of CRISPR/
Cas9-mediated gene editing to restore physiological LAMB3 expres-
sion in keratinocytes derived from JEB patients. The data demon-
strated a safe in situ integration of the therapeutic LAMB3 cDNA
in JEB keratinocytes, and although the adhesion selection protocol
may require further improvement, this novel strategy moves gene
editing for JEB closer to the clinic.
MATERIALS AND METHODS
Vectors and Viral Production
For pCCL.LAMB3.HA.SA-cDNALAMB3pA.HA (IDLV-L.B3) con-
struction, LAMB3 cDNA (3.8 kb in length), spanning from exon 38 Molecular Therapy Vol. 26 No 11 November 2018to 23 and including the splice acceptor of exon 3, was amplified
from MFG-LAMB3.3 Promoterless LAMB3 cDNA was cloned up-
stream of bGH pA signal, between 50 and 30 HA (90 and 413 bp in
length, respectively), both from intron 2 of LAMB3 gene. The donor
cassette was finally cloned in reverse orientation into pCCL.LV.poly-
linker vector,45 generating the transfer plasmid to be packaged into
integration defective lentiviral vector (IDLV-L.B3).
ForAdCas9gRNA construction, pShuttle.CRISPR.gRNA1LAMB3was
generated by cloning fragment U6.gRNA1LAMB3.CBH.hSpCas9.
bGH.pA from plasmid pX330.gRNA1.LAMB3 in pShuttle from
AdEasy Human Adenoviral Vector System (Stratagene). Briefly,
pX330.gRNA1.LAMB3 was obtained by cloning gRNA1LAMB3
in pX330-U6-Chimeric_BB-CBh-hSpCas9 plasmid (Addgene no.
42230) by oligo annealing into BbsI sites (http://www.addgene.org).
Then, pX330.gRNA1.LAMB3 was digested with PciI and NotI, and
fragment U6.gRNA1Lamb3.CBH.hSpCas9.bGH.pA was cloned in
pShuttle from AdEasy (AdEasy Adenoviral Vector System; Strata-
gene), previously digested with NotI and filled in. pShuttle.CRISPR.
gRNA1LAMB3 was linearized with PmeI, de-phosphorylated, and
co-transformedwith pAdEasy-1 fromAdEasy system in BJ5183 bacte-
ria to produce Ad5 genomic plasmid Ad.CRISPR.LAMB3gRNA1.
IDLV viral stocks pseudotyped with vesicular stomatitis virus G pro-
tein were prepared by transient co-transfection of HEK293T cells
with transfer vector, pMD.Lg/pRRE.D64VInt packaging plasmid,
pMD2.VSV-G envelope-encoding plasmid, and pRSV-Rev.20 Vector
particles were concentrated by ultracentrifugation and titrated by
Taqman RT-PCR with PCR primers and 6-carboxyfluorescein
(FAM) probe for WPRE (Applied Biosystems). IDLV-L.B3 titer was
109 vg/mL by qPCR.
AdCas9gRNA vector was produced and titrated as previously
described.46 Adenoviral titer was 1.9  1011 vg/mL by qPCR. The
MOI reported for this virus indicates the amount of vg per cell.
Cell Culture
Primary keratinocytes from JEB patient carrying the homozygous
LAMB3 mutation in exon 14 (c.1945dupG)17 were immortalized to
facilitate clonal analysis. Early-passage primary JEB keratinocytes
were infected with supernatants of pLXSN-based retroviral vector
containing cDNA sequence of E6 and E7 proteins from papilloma vi-
rus type 1647 and referred to as JEB.A649fsX38 keratinocytes. The
karyotype of JEB.A649fsX38 keratinocytes was analyzed (four meta-
phases) as described in Chamorro et al.47 and showed aneuploidy
with redundant trisomy for chromosomes 9 and 20. Chromosome 1,
which hosts LAMB3 gene, was diploid in 50% of analyzed meta-
phases, although in other metaphases, we detected an extra chromo-
some 1 (Figure S11). The second immortalized JEB keratinocytes line
(JEB.R635X) used in this study was established as described in Ham-
mersen et al.18 Feeder layer was required for JEB keratinocyte cell
growth; thus, they were plated onto lethally irradiated 3T3-J2 cells.
JEB.A649fsX38 keratinocytes were cultured in keratinocyte growth
medium (cFAD medium and epidermal growth factor; KC medium),
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Please cite this article in press as: Benati et al., CRISPR/Cas9-Mediated In Situ Correction of LAMB3 Gene in Keratinocytes Derived from a Junctional
Epidermolysis Bullosa Patient, Molecular Therapy (2018), https://doi.org/10.1016/j.ymthe.2018.07.024diluted 1:1 with Cnt-57 (progenitor cell-targeted [PCT] epidermal
keratinocyte medium low bovine pituitary extract [BPE]; CellnTEC
Advanced Cell Systems AG, Bern, Switzerland). JEB.R635X keratino-
cytes were cultured in keratinocyte growth medium (cFAD medium
and epidermal growth factor; KC medium), diluted 1:1 with KGM-
Gold (Lonza; Euroclone, Milan, Italy). Mouse 3T3-J2 cells48 were
grown in DMEM supplemented with 10% donor bovine serum
(Gibco; Thermo Fisher Scientific, Monza, Italy), 50 IU/mL peni-
cillin-streptomycin, and 4 mmol/L glutamine.
Transduction of JEB Keratinocytes, Adhesion Selection, and
Isolation of Single-Cell Clones
For editing analysis, JEB cells were plated 24 hr before transduction
(without feeder layer) and then were transduced with AdCas9gRNA
in serum-free medium containing viral particles at MOIs 104, 2 104,
5  104, or 105 vg/cell. After 1 hr at 37C, the viral mixture was
replaced with Cnt-57 + KC medium. For HR-mediated correction,
JEB keratinocytes (2.5  105) were first infected with IDLV-L.B3
(4.32  102 vg/cell) in suspension, in the presence of polybrene
(8 mg/mL), and seeded in 6-well plates onto lethally irradiated
3T3-J2 cells. After 6 hr, CnT-57 medium was added to cells. After
24 hr, AdCas9gRNA transduction was performed in serum-free
medium containing viral particles at MOIs 104, 2  104, 5  104,
or 105 vg/cell. After 1 hr at 37C, the infection mixture was replaced
with Cnt-57 + KC medium.
To enrich LAMB3-corrected cells, 4 days post-transduction JEB
keratinocytes transduced with IDLV-L.B3 (4.32  102 vg/cell) and
AdCas9gRNA (MOIs 104 and 2  104 vg/cell) were washed with
PBS and incubated with trypsin solution at 37C. Cells that detached
after 4 min of incubation were removed and referred as un-corrected
(negative) JEB cells. Adherent cells were further incubated with
trypsin solution at 37C for additional 4 min and named LAMB3-cor-
rected JEB keratinocytes. After trypsin treatment, cells were plated
onto lethally irradiated 3T3-J2 cells in KC medium diluted 1:1 with
CnT-57. To isolate single-cell clones, JEB.A649fsX38 cells transduced
with IDLV-L.B3 (4.32  102 vg/cell) and AdCas9gRNA (MOIs 104
and 2 104 vg/cell) were limiting diluted, plated onto lethally irradi-
ated 3T3-J2 cells, and cultured inKCmediumdiluted 1:1withCnT-57.
Editing Efficiency Analysis and DNA Sequence Analysis
To analyze editing efficiency and specificity, genomic DNA was
extracted using DNeasy MiniKit (QIAGEN, Milano, Italy). To eval-
uate on-target editing, gRNA target region from JEB cells transduced
at MOI 104, 2 104, 5 104, and 105 vg/cell or un-transduced (mock
transduced) was amplified by PCR (Platinum Taq High Fidelity;
Thermo Fisher Scientific, Monza, Italy), using primers Cel1LamB3for
and Cel1LamB3rev (Table S1), and analyzed with TIDE software to
evaluate indels frequency.
To amplify the off-targets predicted by two public webservers (http://
crispr.mit.edu and CRISPR direct [https://crispr.dbcls.jp]), we de-
signed several primers listed in Table S1. The amplification products
were analyzed by Surveyor assay, according to SURVEYORMutationDetection Kit (Transgenomic, Omaha, NE) manufacturer’s protocol.
Briefly, 72 hr after transduction, PCR amplifications were performed
on genomic DNA and then PCR products were denatured, digested
by Cel-I nuclease, and finally subjected to 2% agarose gel electropho-
resis. 100 bp DNA ladder from New England Biolabs (Massachusetts,
USA) was used as molecular weight marker. For DNA sequence anal-
ysis of on-target indels, PCR products were subcloned into a PCR2.1
TOPO vector (Thermo Fisher Scientific, Monza, Italy) and Sanger
sequenced (Eurofin s.r.l Vimodrone, Italy). Sanger sequences were
analyzed accordingly to a bioinformatics pipeline (D.B., V. Marigo,
and A.R., unpublished data) to accurately evaluate the percentage
and type of indels upon AdCas9gRNA treatment.
PCR and Semiquantitative and qRT-PCR Analyses
Genomic DNA was isolated from JEB cells or skin biopsies with a
QIAmp DNA Mini kit (QIAGEN, S.p.A., Milan, Italy), according to
manufacturer’s protocols. To analyze correct integration of the donor
in LAMB3 locus, we performed target integration PCRs (PCR GoTaq,
Promega, Milan Italy) on genomic DNA using primers TI50LamB3for
and TI50LamB3rev to analyze the correct integration at 50 region and
primers TI30LamB3for and TI30LamB3rev to analyze the correct inte-
gration at 30 region (see Table S2 for primers list). PCR cycles for TI50
are 95C 30 s, 57C 30 s, and 72C 30 s; PCR cycles for TI30 are 95C
30 s, 55C 30 s, and 72C 1 min. PCR products were loaded on 1%
agarose gel, and 1 kb or 100 bp DNA ladders from New England Bio-
labs (Massachusetts, USA) were used as molecular weight markers.
To investigate the integration of the 50 end of IDLV vector, we
performed modified target integration 30 PCR (TaKaRa LA Taq,
USA) on genomic DNA using primers TI30LamB3for and LamB3-
Ex3-RC. PCR cycles are as follows: 98C 30 s; 60C 30 s; and 68C
2 min. For allelic discrimination, a three-primer-based PCR (TaKaRa
LA Taq, USA) was performed to discriminate between parental
allele (TI50LamB3for and TI30LamB3rev) and donor-integrated allele
(TI50LamB3for and TI50LamB3rev). PCR cycles are as follows: 98C
20 s; 55C 30 s; and 68C 5 min.
Total RNA from JEB cells or skin biopsies was isolated with RNeasy
Mini kit plus (QIAGEN, Milan, Italy), according to manufacturer’s
protocols. cDNA from JEB cells was synthesized in a 20 mL reaction
using 200 ng total RNA and ImProm-II Reverse Transcription System
(Promega, Milan, Italy). cDNA from skin biopsies was synthesized in
a 20-mL reaction using 400 ng and SuperScript III (Life Technologies,
Monza, Italy).
To evaluate LAMB3 mRNA expression, semiquantitative RT-PCR
was performed with primers LamB3Exon13_F and LamB3Exon15_R.
PCR cycles are as follows: 95C 30 s; 60C 30 s; and 72C 45 s. As
housekeeping control, GAPDH mRNA was amplified with primers
GAPDH-F and GAPDH-R. PCR cycles are as follows: 95C 30 s;
60C 30 s; and 72C 45 s.
qRT-PCR was performed in 96-well plates on ABI Prism 7900
Sequence Detection System (Applied Biosystems, Monza, Italy)Molecular Therapy Vol. 26 No 11 November 2018 9
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sion assay (Applied Biosystems), with a final reaction of 25 mL.
PCR primers and 6-carboxyfluorescein (FAM) probes for GAPDH
(Hs99999905_m1) or LAMB3 (Hs00989722_m1) were purchased
from Applied Biosystems. Reactions were performed according to
manufacturer’s instructions. The relative expression was normalized
to the level of GAPDH in the same cDNA using 2-DDCt quantification.
The mean of replicated relative quantity (RQ) values for each sample
was calculated.
Flow Cytometry
For flow cytometric analysis of LAMB3 expression, after washing with
PBS + 5% fetal bovine serum (FBS) + 2.5 mM EDTA, JEB cells were
stained with antigen-presenting cell (APC)-conjugated anti-feeder
antibody (Miltenyi Biotec, Bologna, Italy) accordingly to manufac-
turer’s protocol. Cells were fixed and permeabilized using the Fix
and Perm cell permeabilization reagents kit (Invitrogen, Monza,
Italy), according to manufacturer’s protocol, before intracellular
staining of LAMB3 with anti-b3 chain monoclonal antibody K140
(diluted 1:30; a kind gift from Prof. Castiglia, Istituto Dermopatico
dell’Immacolata, IRCCS, Rome, Italy). As secondary antibody, Alexa
488 donkey anti-mouse antibody (Life Technologies, Monza, Italy;
1:1,000) was used. Fluorescence was acquired on a FACS CANTO
cytofluorimeter (BD Biosciences, Milan, Italy). Intracellular LAMB3
expression was evaluated after feeder exclusion (APC cells). The
percentage of LAMB3-positive cells was determined after subtracting
the percentage of LAMB3-positive events in untreated cells. All
flow cytometry experiments were analyzed with the FlowJo software
(Tree Star).
Western Blotting
Cell lysates were extracted with radioimmunoprecipitation assay
(RIPA) buffer containing proteinase inhibitor cocktail (Complete
Mini, EDTA-free; Roche Diagnostics, Monza, Italy), incubated for
30 min on ice and centrifuged at 14,000 rpm for 30 min. The amount
of proteins was determined using Bradford assay (Bio-Rad, Milan,
Italy). Sixty micrograms of JEB keratinocytes extracts and 10 mg of
primary keratinocyte extracts were separated on 4%–12% gradient
NuPAGE Bis-Tris Gel (Life Technologies, Monza, Italy) under
reducing condition. Western blots were performed with a mouse
monoclonal antibody against human Kalinin B1 (Kalinin B; 1:1,000;
BD Transduction Laboratories, Milan, Italy). Kalinin B1 is an alterna-
tive name of laminin subunit beta-3 protein coded by LAMB3 gene
according to Uniprot (https://www.uniprot.org/uniprot/Q13751).
For protein loading normalization, a mouse monoclonal antibody
anti-b-actin (sc-81178; 1:1,000; Santa Cruz Biotechnology, Heidel-
berg, Germany) was used. Horseradish-peroxidase-conjugated anti-
mouse antibody (diluted 1:5,000) was used for chemiluminescent
detection (Amersham; GE Healthcare Europe, Milan, Italy).
Keratinocyte Growth and Detachment Analysis
JEB clone proliferation was measured by MTT reduction colorimetric
assay (Sigma-Aldrich, Milan, Italy). For the time course analysis,
4  104 cells/well were plated without feeder layer in KC medium10 Molecular Therapy Vol. 26 No 11 November 2018diluted 1:1 with CnT-57, a well of a 24-well plate per time point,
and incubated at 37C for 24, 48, 72, or 96 hr. At each time point, cells
were incubated with 500 ng/mL MTT solution at 37C for 90 min,
and then MTT solution was gently removed. The incorporated dye
was solubilized in acidified isopropanol and determined by absor-
bance measurement (A570nm). Results are expressed as fold change
from untreated control cells at 24 hr, which is set at 1 and as mean
of 3 independent experiments.
Detachment time analysis was performed by measuring the time
of incubation with trypsin solution necessary to all cells of a sub-
confluent culture to lose adhesive properties.
Bioengineered Skin Preparation and Grafting on
Immunodeficient Mice
The SE or bioengineered skin corresponds to a 3D culture resembling
the basic architecture of skin. It comprises a dermal hydrogel
matrix (fibrin) containing embedded live human fibroblasts and an
epidermal component formed by human keratinocytes (genetically
corrected or non-corrected) added to the dermal matrix and grown
until confluence (keratinocyte layer). Bioengineered skin grafts were
prepared from 4 samples: 2 LAMB3-corrected clones; 1 negative
clone; and untreated JEB.A649fsX38 cells as previously described.49
Bioengineered SEs were grafted subcutaneously in the back of immu-
nodeficient nu/nu mice (n = 3/sample) according to Barrandon
et al.49 Four weeks after grafting, mice were sacrificed and grafts
harvested for skin immunohistochemistry and molecular analysis.
Animal studies were approved by our institutional animal care and
use committee according to all legal regulations.
Immunofluorescence and Immunohistochemistry
Immunofluorescence analysis for laminin 332 expression on skin
biopsies from mice was performed on 7-mm sections. After blocking
with 10% fetal bovine serum + 3% BSA in PBS, sections were incu-
bated with 50 mg/mL unconjugated Fab anti-immunoglobulin G
(IgG) antibody. After wash, sections were incubated with mouse
monoclonal GB3 antibody (diluted 1:5; a kind gift from Prof. Cas-
tiglia, Istituto Dermopatico dell’Immacolata, IRCCS, Rome, Italy).
As secondary antibody, Alexa 488 donkey anti-mouse antibody
(Life Technologies; 1:1,000) was used. Staining with 0.1 mg/mL
DAPI was performed for nuclear staining. Slides were mounted
with Dako Fluorescent Mounting Medium (Dako Italia SRL,
Milan, Italy) and analyzed with a Zeiss Axioskop 40 FL fluorescence
microscope equipped with a digital camera AxioCam and
AxioVisionRel version 4.8 software for image processing (Carl Zeiss,
Milan, Italy).
Histological samples of the whole mouse-human skin “sandwich”
were formalin fixed and H&E stained as described in Chamorro
et al.47
Statistical Analysis
Two-way ANOVA or Student’s t test was performed for statistical sig-
nificance. All values in each group were expressed as mean ± SEM.
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